HB5526, the "Biosimilar Red Tape Elimination Act," would change federal law governing biosimilar biological products by making interchangeability largely automatic once a biosimilar is licensed under section 351(k) of the Public Health Service Act. Under the bill, a biosimilar would generally be deemed interchangeable with its reference product upon licensure, rather than requiring a separate FDA determination based on additional switching data. The bill also creates transition rules for products already licensed or awaiting exclusivity periods, preserving existing first-interchangeable exclusivity for certain products and delaying deemed interchangeability in limited cases.
The bill further directs the Secretary of Health and Human Services to update or replace FDA guidance on interchangeability and biosimilar review within specified timeframes, including revising the agency’s 2019 and 2024 interchangeability guidance documents. It also makes conforming amendments to related provisions in the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, including clarifying that biosimilar products licensed under section 351(k) are not treated as having a new active ingredient in most pediatric-review contexts. The legislation expressly states that it does not change the underlying biosimilar licensure standard or limit FDA’s ability to require information needed to support biosimilar approval.
Impact
If enacted, the bill would substantially alter the federal regulatory pathway for biosimilar products by removing the separate interchangeability hurdle for most newly licensed biosimilars and by converting interchangeability into a default status tied to licensure. This would affect FDA review practices, manufacturer exclusivity expectations, pharmacy substitution dynamics, and the timing of market entry for biosimilar competitors. It would also require FDA to revise guidance and conform related statutory references in the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.
Sentiment
Based on the bill text and available context, the measure appears to be framed positively as a deregulatory or efficiency-focused reform, with sponsors presenting it as a way to reduce unnecessary barriers for biosimilar competition. There is no recorded committee debate or vote history in the provided materials, so no formal opposition or support can be measured from proceedings. The title and structure suggest an intent to streamline FDA requirements while preserving core safety and licensure standards.
Contention
The main policy tension is between reducing regulatory burden and preserving the FDA’s traditional role in determining interchangeability through additional evidence. Supporters are likely to favor faster biosimilar uptake, lower development costs, and greater competition in biologic drug markets. Potential critics may worry that automatic interchangeability could reduce the amount of switching data available to regulators, affect confidence in substitution at the pharmacy level, or alter the balance of exclusivity protections for existing interchangeable biosimilars. The bill attempts to address some of these concerns by preserving existing exclusivity periods and stating that it does not change the biosimilar licensure standard.